DYADIC
Our Pipeline
Dyadic International, Inc. (NASDAQ: DYAI)
We are a global biotechnology company committed to building disruptive microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health.
With a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary filamentous fungal based
Microbial Platforms are the Foundation of Our Core Business Segments
C1 Platform: Pharmaceutical Applications
Vaccines
- Antigens in higher yields and less time for more efficiency
- C1 faster production and higher yields can speed development
Lower COGS provide enhanced pricing flexibility Business Development
- C1 platform can be licensed for production of recombinant protein vaccines
- Research licenses available
- Production strains can be developed and licensed
- Dyadic Production strains available in select infectious and other diseases such as:
Therapeutic Proteins
- C1 mAbs neutralize viruses virtually identical to CHO produced mAbs
- C1 cells have been glycoengineered to express mAbs with human like glycan structures (~99%)
- C1 mAbs are correctly folded, bind virtually identical to CHO produced mAbs
Business Development
- C1 platform can be licensed for production of therapeutic proteins
- Research licenses available
- Production strains for therapeutic proteins can be developed and licensed
- Dyadic Production strains available in select infectious and other diseases such as:
- Nivolumab, certoluzimab, others in development
Alternative Proteins
- C1 mAbs neutralize viruses virtually identical to CHO produced mAbs
- C1 cells have been glycoengineered to express mAbs with human like glycan structures (~99%)
- C1 mAbs are correctly folded, bind virtually identical to CHO produced mAbs
Business Development
- Dapibus™ platform can be licensed for production of recombinant proteins, enzymes, metabolites, precursors, and other targets.
- Research licenses available
- Production strains for proteins can be developed and licensed
- Dyadic Production strains available for select products and grades such as:
- Human and bovine serum albumin, select endonucleases, Fc insulin, cannabinoid, nicotinamide riboside.
Human Health
Animal Health
